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ABSTRACT  71 
The information obtained from the chemical analysis of specific human excretion products 72 
(biomarkers) in urban wastewater can be used to estimate the exposure or consumption of the 73 
population under investigation to a defined substance. A proper biomarker can provide relevant 74 
information about lifestyle habits, health and wellbeing, but its selection is not an easy task as it 75 
should fulfil several specific requirements in order to be successfully employed. This paper aims to 76 
summarize the current knowledge related to the most relevant biomarkers used so far. In addition, 77 
some potential wastewater biomarkers that could be used for future applications were evaluated. For 78 
this purpose, representative chemical classes have been chosen and grouped in four main categories: 79 
(i) those that provide estimates of lifestyle factors and substance use, (ii) those used to estimate the 80 
exposure to toxicants present in the environment and food, (iii) those that have the potential to 81 
provide information about public health and illness and (iv) those used to estimate the population 82 
size. To facilitate the evaluation of the eligibility of a compound as a biomarker, information, when 83 
available, on stability in urine and wastewater and pharmacokinetic data (i.e. metabolism and 84 
urinary excretion profile) has been reviewed. Finally, several needs and recommendations for future 85 
research are proposed.  86 
 87 
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INTRODUCTION 91 
Relevant epidemiological information about lifestyle habits, public health and wellbeing can 92 
be obtained from the chemical analysis of urban wastewater. This approach, called wastewater-93 
based epidemiology (WBE), is based on the analysis of specific human metabolic excretion 94 
products (biomarkers) in wastewater as indicators of consumption or exposure of the population 95 
served by the sewer network under investigation to different substances. WBE has been 96 
successfully applied as a suitable approach for the estimation of illicit drugs consumption (Ort et al., 97 
2014; Thomaidis et al., 2016; Thomas et al., 2012; van Nuijs et al., 2011a; Zuccato et al., 2008), but 98 
it has also recently been employed to assess other lifestyle-related factors such as alcohol 99 
(Rodríguez-Álvarez et al., 2015; Ryu et al., 2016), nicotine (Castiglioni et al., 2015b; Lopes et al., 100 
2014; Rodríguez-Álvarez et al., 2014b), caffeine (Senta et al., 2015a) and new psychoactive 101 
substances (NPS) (Kinyua et al., 2015; Reid et al., 2014a; van Nuijs et al., 2014). WBE has also 102 
been applied to verify community-wide exposure to endocrine disruptors and antimicrobial agents 103 
in personal care and household products (O’Brien et al., 2015; Rydevik et al., 2015). The broad 104 
range of information that can be gathered from wastewater opens up the possibility of expanding 105 
WBE to other human biomarkers providing clues about diet, health, diseases and exposure to 106 
contaminants. For example by linking exposure to environmental or food contaminants with health 107 
outcomes such as diabetes or cancer. 108 
In general, a human biomarker can be an endogenous compound (produced naturally in the 109 
body) or a metabolite of a xenobiotic/exogenous substance (produced through metabolic processes 110 
after intentional consumption of a substance, accidental exposure to environmental contaminants, as 111 
well as through diet or ingestion of a substance). Biomarkers can be classified on the basis of their 112 
function as biomarkers of exposure (compounds that give information about substances consumed 113 
or ingested) and biomarkers of effect (indicators of measurable changes or alterations in an 114 
organism that can be associated with health problems or wellbeing) and on the basis of biological 115 
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nature (e.g. metabolites, hormones), or of the disease they can indicate (e.g. cardiovascular 116 
biomarkers, obesity biomarkers) (Pischon, 2009).  117 
The selection of a specific biomarker is not an easy task, as it needs to satisfy different 118 
criteria (Figure 1) (Castiglioni and Gracia-Lor, 2015; Gracia-Lor et al., 2016). From a WBE 119 
perspective, a suitable biomarker must be excreted mainly via urine and concentration levels in 120 
urine should be at least in the µg/L range to ensure its detection in raw wastewater after dilution 121 
(Chen et al., 2014).  122 
 123 
Excreted via urine 
in consistent amounts 
Detectable in wastewater
Stable in wastewater
Unique source: human metabolism
Requirements of:
• Lifestyle and 
substance use 
biomarkers
• Exposure biomarkers 
from environment 
and food
• Health biomarkers
Low variance in the per capita daily excretion
Daily  per capita excretion not affected by independent 
variables (season, weather or geographic location)
Requirements of:
• Population 
biomarkers
 124 
Figure 1. Main requirements of a biomarker 125 
 126 
A biomarker should also be sufficiently stable in wastewater during the transport (in-sewer 127 
stability) from the input (i.e. toilet) to the sampling point and during sampling, storage and analysis 128 
(in-sample stability) (McCall et al., 2016a). In wastewater biomarkers can undergo further 129 
transformation due to microbial activity (Mardal and Meyer, 2014) and/or sorption to particulate 130 
matter (Baker and Kasprzyk-Hordern, 2011; Daughton, 2012a; McCall et al., 2016a). The fate of 131 
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biomarkers in the sewer can be also predicted by using mathematical models to simulate 132 
physicochemical and microbial processes (Bisceglia and Lippa, 2014; McCall et al., 2016b; Ramin 133 
et al., 2016). It is important to note that biomarker transformation pathways in the sewer might be 134 
different from human metabolic pathways.  135 
Furthermore, a biomarker should preferably be specific to the compound under investigation 136 
and unique to human metabolism, thus ensuring that its presence only derives from human 137 
excretion and not from exogenous sources (Daughton, 2012b). Therefore, pharmacokinetic data on 138 
human metabolism are necessary but unfortunately this information is not always feasible as for 139 
many substances it is very limited or do not even exist. This information, however, is highly 140 
relevant not only to back-calculate the consumption/exposure of/to a certain substance by a 141 
community, but also to distinguish the amount of a substance originating from human metabolism 142 
or other sources. Unfortunately, pharmacokinetic studies are time-consuming and have to fulfil 143 
strict ethical rules. Alternative approaches, which allow for the identification and selection of 144 
appropriate biomarkers, are therefore required; for example, in-vitro studies using liver enzymes, 145 
which metabolize the parent compound, help in the elucidation of the chemical structure of the 146 
metabolites formed (i.e. possible biomarkers) formed (Mardal et al., 2016). Computer-based in-147 
silico modelling also allow the prediction of pharmacokinetics (Reid et al., 2014a). However these 148 
alternatives provide qualitative information on metabolism, but not data regarding excretion rates of 149 
parent substances and their metabolites (Gracia-Lor et al., 2016). 150 
The present manuscript emerges within the framework of the pan-European inter-151 
disciplinary network (Sewage analysis CORE group-SCORE), which brings together experts from 152 
different disciplines interested in standardizing the WBE approach and in coordinating international 153 
studies (http://score-cost.eu/). The aim of this review is to describe the criteria for selecting suitable 154 
biomarkers and to give an overview of relevant human (urinary) metabolites and potential 155 
wastewater biomarkers. Biomarkers have been grouped in four sections: (i) those that provide 156 
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estimates of lifestyle factors and substance use, (ii) those used to estimate the exposure to toxicants 157 
present in the environment and food, (iii) those giving information about public health and (iv) 158 
those used to estimate the population size. For each group and biomarker, a thorough review of the 159 
available pharmacokinetic data (i.e. metabolism and excretion profile) and stability in urine and 160 
wastewater (if known) is provided. This information can be used to evaluate their suitability 161 
according to the criteria described above. Finally, potential gaps or limitations are discussed and 162 
future research directions are proposed.  163 
 164 
2. LIFESTYLE AND SUBSTANCE USE BIOMARKERS  165 
Initially, WBE was applied to evaluate lifestyle, in particular illicit drug use within a 166 
community. Its ability to deliver objective and near-real-time data on drug use, being able to detect 167 
changes over time and local patterns of use, suggests that this method can be used as a 168 
complementary and extended data source to existing epidemiological tools. WBE has been well 169 
established for monitoring the use of cocaine, cannabis, amphetamine, methamphetamine and 170 
MDMA (3,4-methylenedioxymethamphetamine).  171 
Additional applications to estimate consumption of other substances, such as alcohol, 172 
tobacco, caffeine and NPS, have been employed more recently. Alcohol and nicotine (tobacco) are 173 
probably the most popular and accepted recreational drugs. However, many negative social, 174 
economic and health aspects have been linked to their use, causing millions of deaths every year 175 
(World Health Organization, 2015, 2014). It is therefore important and of particular interest for 176 
policy makers to obtain continuous monitoring data on consumption levels and patterns of use, in 177 
order to reduce the disease burden related to alcohol and tobacco use. Caffeine use has been 178 
limitedly investigated, although it is one of the most extensively used legal stimulants, found in 179 
widely-consumed products, such as coffee, tea, soft and “energy” drinks. Besides monitoring its 180 
consumption, caffeine has also been proposed as a human biomarker for assessing the size and 181 
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dynamics of the population served (see section 5.3) by a particular wastewater treatment plant 182 
(WWTP) (Senta et al., 2015a). NPS are emerging narcotic or psychotropic substances which may 183 
pose similar threats to public health such as classical illicit drugs (European Union, 2005; Papaseit 184 
et al., 2014). Due to the delay between their appearance on the market and their addition to the list 185 
of banned (or controlled) substances, many NPS can be legally purchased, thus promoting their 186 
proliferation worldwide. Furthermore, new substances appear continuously on the market (Bijlsma 187 
et al., 2016; EMCDDA, 2015a). WBE has been proposed as a tool for providing useful information 188 
on temporal and regional trends in the use of NPS.  189 
Current state and some new features of WBE, with regard to lifestyle and substance use are 190 
presented in this chapter. Furthermore, specific biomarkers of each lifestyle factor are suggested 191 
(Table S1) and conceptual approaches for dealing with NPSs using biomarkers in wastewater are 192 
proposed. 193 
 194 
2.1. Illicit drugs 195 
Among the available epidemiological indicators, general population surveys have been 196 
traditionally used to assess illicit drug use at the population level. Yet, due to their inherent biases, 197 
complementary and real-time approaches are needed. The determination of illicit drug consumption 198 
through wastewater was first theorized by Daughton (Daughton, 2001) and implanted by Zuccato et 199 
al. using cocaine as an example (Zuccato et al., 2005). Since then, WBE has been widened to 200 
include other illicit drugs (Asimakopoulos and Kannan, 2016; Castiglioni et al., 2008; Hernández et 201 
al., 2016; van Nuijs et al., 2011a).  202 
The biomarkers currently used are either the illicit drug itself (i.e. amphetamine, 203 
methamphetamine, and 3,4-methylenedioxy-methamphetamine-MDMA) or one of its metabolites 204 
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(i.e. benzoylecgonine (BEG) for cocaine, 11-nor-9-carboxy-delta9-tetrahydrocannabinol (THC-205 
COOH) for cannabis and morphine or 6-acethylmorphine for heroin). 206 
Cocaine, the first substance studied in WBE, is considered unstable in wastewater; however, 207 
its unique and stable metabolite (BEG) makes back-calculation to drug consumption more 208 
straightforward. It must be noted that significant degradation of BEG from cocaine in sewage is also 209 
reported (Plósz et al., 2013), which could result in over estimation of cocaine consumption if this 210 
formation is neglected. Considering human excretion rates, a cocaine: BEG ratio around 0.1 or 211 
lower can indicate consumption, and any value higher (between 0.1 and 0.7) could indicate other 212 
sources of cocaine, such as direct disposal (Castiglioni et al., 2011a). However, more research is 213 
needed in this regard (Bijlsma et al., 2012; Postigo et al., 2010; Van Nuijs et al., 2009).  214 
Δ9-tetrahydrocannabinol (THC), the active ingredient of cannabis, is metabolized to more 215 
than 20 metabolites after consumption, with 11-nor-∆9-carboxy-THC (THC-COOH) and 11-216 
hydroxy-THC (THC-OH) being those primarily excreted. THC-COOH has been shown to be highly 217 
stable and is thus normally used to estimate cannabis consumption, albeit with some analytical 218 
difficulties arising in multi-residue methods resulting from its non-polarity compared to other illicit 219 
drugs (Bijlsma et al., 2014; Ort et al., 2014; Pedrouzo et al., 2011).  220 
Two more recently works studied illicit drugs are ketamine and methadone. Ketamine is a 221 
dissociative anaesthetic which has been used as a recreational drug, whilst methadone is a synthetic 222 
opioid used clinically to relieve pain and also as maintenance treatment of opioid addicts 223 
(Castiglioni et al., 2011b; Preston et al., 2003). Both ketamine and its metabolite norketamine are 224 
fairly stable in wastewater (Castiglioni et al., 2015a; McCall et al., 2016a), with the parent 225 
compound generally used as a biomarker for reliable estimation of drug usage. Variable stability for 226 
methadone has, however, been reported i.e. from high (Senta et al., 2014) to low (González-Mariño 227 
et al., 2010).  228 
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Opioids use in Europe remains a central issue, reflecting the significant impact these drugs 229 
still have on mortality and morbidity (EMCDDA, 2015b). In recent years, the production of high 230 
purity heroin has been rising, thereby increasing heroin-related mortality (UNODC, 2015). In the 231 
human body, heroin is rapidly hydrolyzed to 6-monoacetylmorphine (6-MAM) by blood esterases 232 
(Bencharit et al., 2003) and further hydrolyzed to morphine in the liver (Smith, 2009). In 233 
wastewater, heroin shows low stability (González-Mariño et al., 2010). Although 6-MAM detected 234 
in urine is used as a marker of heroin consumption (Staub et al., 2001), 6-MAM is not always 235 
detected in wastewater as it is not stable in wastewater (Thai et al., 2014). Back-calculations using 236 
6-MAM as biomarker provides inconsistent results (Been et al., 2015). Therefore, morphine is 237 
considered as an alternative biomarker for heroin. However, therapeutic consumption of morphine 238 
should be subtracted from the total measured morphine in sewage (Khan and Nicell, 2011; van 239 
Nuijs et al., 2011a; Zuccato et al., 2016), which necessitates the availability of registered prescribed 240 
morphine at the time of wastewater sampling. Morphine is also formed in the sewer due to 241 
deconjugation of morphine glucuronide and deacetylation of 6-MAM, which imposes new 242 
challenges in back-calculation schemes. Although fractions of morphine originating from codeine 243 
can be considered negligible (Zuccato et al., 2008), more research is needed to find a drug 244 
biomarker for heroin which fulfils all the aforementioned criteria.  245 
As shown in Table 1, the most frequently used illicit drug biomarkers are benzoylecgonine, 246 
amphetamine, methamphetamine, MDMA and THC-COOH (Thomas et al., 2012). Information 247 
about excretion and stability in urine and wastewater of these and other illicit drug biomarkers less 248 
frequently studied is presented in Table S1.One of the most current analytical challenges associated 249 
with WBE is represented by chirality. Amphetamine, methamphetamine and MDMA are among the 250 
illicit drugs that are chiral and as a result they can exist as enantiomers (one enantiomeric pair per 251 
each chiral centre). The verification of their chiral signature in wastewater (i.e. relative proportion 252 
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of two enantiomers within each enantiomeric pair) allows to distinguish between illicit or licit use 253 
and direct disposal (Emke et al., 2014). It has been shown that the distinction between the 254 
consumption or the disposal of MDMA could be made by differentiating the loads of the 255 
enantiomers present in wastewater. Indeed, enantiomeric fractions (EFs) greater than 0.5 indicated 256 
illicit use, whilst EFs equal to 0.5 indicated direct disposal, when EF was calculated as follows:  257 
 258 
Enantiomeric profiling of MDMA’s metabolites were recently investigated in wastewater by 259 
Castrignanò et al., suggesting enantioselective metabolism for HMMA (Castrignanò et al., 2016). 260 
Amphetamine and methamphetamine can also be investigated at enantiomeric level, however due to 261 
both legal and illicit uses, a clear understanding between consumption and direct disposal is 262 
difficult (Emke et al., 2014; Kasprzyk-Hordern and Baker, 2012).  263 
 264 
2.2.  Alcohol 265 
Following the consumption of alcoholic beverages, the majority of ingested ethanol is 266 
rapidly metabolized in the human body in a two-stage oxidation process, first to acetaldehyde and 267 
then to acetic acid. The remaining part is excreted unchanged in urine, sweat and exposed breath 268 
(Jones, 1990). However, a very small fraction (<0.1%) undergoes a conjugation reaction with 269 
glucuronic acid to produce ethyl glucuronide (EtG) (Dahl et al., 2002) and with 3'-270 
phosphoadenosine 5'-phosphosulfate to produce ethyl sulphate (EtS) (Helander and Beck, 2005). 271 
These metabolites are excreted within a few hours and are detectable in urine for considerably 272 
longer times (up to 1-2 days, depending on the subject and the alcohol dose) (Helander and Beck, 273 
2005; Høiseth et al., 2008), making them unequivocal indicators of recent alcohol consumption 274 
(Dahl et al., 2011; Dresen et al., 2004).  275 
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EtG was found to degrade ~50% after 18 hours, whereas EtS showed little or no degradation 276 
(Reid et al., 2011). In addition, no significant differences were found between its stability in sewage 277 
and in an ethanol-fortified wastewater sample (Reid et al., 2011), indicating that it is unlikely to be 278 
formed from unconsumed alcohol discarded into the sewer system. Taking into account these 279 
observations, EtS has been used by several researchers to estimate community-wide alcohol 280 
consumption through wastewater analysis (Table 1). Typically, its determination in this matrix is 281 
performed by direct injection, after filtration and/or centrifugation, into a liquid chromatography-282 
mass spectrometry system. The alcohol consumption rates estimated through WBE have revealed 283 
specific drinking patterns, temporal and spatial variations. The study conducted by Reid et al. (Reid 284 
et al., 2011), for example, clearly showed the weekend elevated drinking pattern in Oslo. 285 
Furthermore, the estimated consumption rates were in good agreement with sales statistics (Reid et 286 
al., 2011). The increase in alcohol consumption during the weekend was also found in three Spanish 287 
cities, eight Belgian cities an done Italian city (Andrés-Costa et al., 2016; Boogaerts et al., 2016; 288 
Mastroianni et al., 2014; Rodríguez-Álvarez et al., 2015, 2014a; Ryu et al., 2016). However, a 289 
different consumption pattern was observed during a special event in Valencia, where an increased 290 
alcohol use was noticeable, reaching the maximum rate on Wednesday, which corresponded to the 291 
last day of the “Fallas” festivities (Andrés-Costa et al., 2016). Co-consumption of alcohol and 292 
cocaine was also evaluated through WBE by analyzing cocaethylene, a specific biomarker excreted 293 
when the two substances are consumed together (Mastroianni et al., 2014; Rodríguez-Álvarez et al., 294 
2015). In the studies carried out in Belgium (Boogaerts et al., 2016) and Greece (Gatidou et al., 295 
2016) higher alcohol consumption in urbanized cities than in smaller villages was evidenced. 296 
Although all these studies highlight the potential of EtS as a reliable biomarker for estimating 297 
alcohol consumption in relative terms, the main limitation is the uncertainty associated with its 298 
percentage of excretion, which might lead to inaccurate back-calculations in absolute amounts. 299 
Until now, there have been insufficient pharmacokinetic studies evaluating this percentage to 300 
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provide a unique, representative figure (Halter et al., 2008; Høiseth et al., 2008; Lostia et al., 2013; 301 
Schneider and Glatt, 2004; Wurst et al., 2006). In the aforementioned WBE studies, the range 302 
0.010-0.016% (on molar basis) was used by (Andrés-Costa et al., 2016; Reid et al., 2011); the 303 
median value of the excretion rates provided by Høiseth et al. (Høiseth et al., 2008), 0.011%, was 304 
used by (Mastroianni et al., 2014; Rodríguez-Álvarez et al., 2014a). Finally, four studies (Boogaerts 305 
et al., 2016; Gatidou et al., 2016; Rodríguez-Álvarez et al., 2015; Ryu et al., 2016), employed a 306 
people-weighted value of 0.012%, based on the data provided by (Høiseth et al., 2008) and (Wurst 307 
et al., 2006).  308 
 309 
2.3.  Tobacco  310 
Nicotine is the principal alkaloid found in tobacco and, although not being directly 311 
associated with diseases, its addictiveness is the major cause of continued use of tobacco products 312 
(Hukkanen, 2005). Nicotine is extensively metabolized in humans, with 70-80% of the initial dose 313 
being converted to cotinine (Benowitz and Jacob, 1994), which is then further metabolized into 314 
various compounds, the most abundant being trans-3’-hydroxycotinine (Byrd et al., 1992). Nicotine 315 
and its major metabolites are also excreted as glucuronides. Globally, nicotine is excreted 316 
unchanged at rates between 8 and 10%, whilst its glucuronide makes up for 3-5% of the initial dose 317 
(Byrd et al., 1992). Cotinine and its glucuronide are excreted at rates between 10-15% and 12-17%, 318 
respectively, while trans-3’-hydroxycotinine and its glucuronide make up for 33-40% and 7-9% of 319 
the initial dose, respectively (Hukkanen, 2005).   320 
Nicotine and its metabolites, cotinine and trans-3’-hydroxycotinine, have been analyzed in 321 
wastewater as biomarkers (Table S1) to estimate tobacco use in various communities (Castiglioni et 322 
al., 2015b; Lopes et al., 2014; Mackuľak et al., 2015; Rodríguez-Álvarez et al., 2014b; Senta et al., 323 
2015a). The three compounds were shown to be stable in wastewater samples stored at 4° C and 20° 324 
C during 24 h (Chen et al., 2014; Rodríguez-Álvarez et al., 2014b; Senta et al., 2015a). However, 325 
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the concentration of the glucuronide of trans-3’-hydroxycotinine was shown to decrease even in 326 
refrigerated samples (i.e., 35% decrease over 8 h at 4° C). The authors of the study thus suggested 327 
to enzymatically deconjungate the compounds prior to extraction and analysis (Rodríguez-Álvarez 328 
et al., 2014b).  329 
The amounts of these compounds in wastewater range from 0.1 to 7 µg/L (Buerge et al., 330 
2008; Mackuľak et al., 2015; Rodríguez-Álvarez et al., 2014b; Senta et al., 2015a), and the levels of 331 
cotinine and trans-3’-hydroxycotinine reflected the excretion profiles expected from 332 
pharmacokinetic studies, whilst nicotine was found at higher levels (Rodríguez-Álvarez et al., 333 
2014b; Senta et al., 2015a). The contribution from ashes and cigarettes butts has been advanced as a 334 
possible explanation for this observation (Castiglioni et al., 2015b; Rodríguez-Álvarez et al., 2014b; 335 
Senta et al., 2015a). In fact, higher nicotine levels have been reported during rain events, supporting 336 
the hypothesis that ashes and cigarette butts found on streets eventually contribute to measured 337 
nicotine loads (Senta et al., 2015a). Thus, cotinine and trans-3’-hydroxycotinine were used as 338 
biomarkers to estimate the amount of nicotine used per capita in a population, as indicated in Table 339 
1 (Castiglioni et al., 2015b; Mackuľak et al., 2015; Rodríguez-Álvarez et al., 2014b; Senta et al., 340 
2015a). 341 
In some studies, figures were corrected to account for the portion of nicotine absorbed 342 
during smoking (Castiglioni et al., 2015b; Mackuľak et al., 2015), thus providing estimates of the 343 
gross amount of number of cigarettes. Additionally, Mackul’ak and co-workers (Mackuľak et al., 344 
2015) included a factor to account for losses due to degradation, based on the mean residence time 345 
of wastewater in sewers. From the estimated nicotine consumption, the number of cigarettes 346 
smoked per capita was also calculated using as reference value 0.8 mg of nicotine per cigarette 347 
(Gorrod and Wahren, 1993; Lopes et al., 2014; Rodríguez-Álvarez et al., 2014b) or 1.25 mg of 348 
nicotine (Castiglioni et al., 2015b). The obtained figures highlighted substantial differences in 349 
consumption within the same country. For example, researchers from Italy found significant 350 
16 
 
differences between the north, centre and south of the country (Castiglioni et al., 2015b; Senta et al., 351 
2015a). These results were in agreement with epidemiological data, which suggested a higher 352 
prevalence of tobacco use in the south (Castiglioni et al., 2015b). Similarly, important differences 353 
were found in cities in Slovakia and Spain (Mackuľak et al., 2015; Rodríguez-Álvarez et al., 354 
2014b). In Portugal, estimates of nicotine consumption derived from wastewater analysis were in 355 
line with findings from a European survey (Lopes et al., 2014).  356 
Mass loads measured in wastewater were also used to investigate weekly consumption 357 
patterns and findings suggested that this was stable throughout the week (Chen et al., 2014; 358 
Rodríguez-Álvarez et al., 2014b; Senta et al., 2015a). Public holidays and specific touristic 359 
locations, attracting larger crowds, were the only exceptions (Lopes et al., 2014; Mackuľak et al., 360 
2015). 361 
The results obtained show that the measurement of nicotine metabolites is a useful tool 362 
which could potentially be used to complete current knowledge about the prevalence of tobacco 363 
use. 364 
 365 
2.4. Caffeine 366 
Caffeine (1,3,7-trimethylxanthine) is the world's most widely consumed stimulating agent 367 
(Garattini, 1993). It is found in many globally popular products, including tea and cola drinks, as 368 
well as in some medications and dietary supplements, but the most important source of this alkaloid 369 
is coffee. 370 
Caffeine metabolism is extensive (Baselt, 2004), with at least 17 urinary metabolites 371 
identified in humans (Garattini, 1993). The major metabolites include 1-methyluric acid (excretion 372 
rate 12-25%), 1-methylxanthine (9-18%), 7-methylxanthine (2-8%), paraxanthine (1,7-373 
dimethylxanthine; 4-7%), 1,7-dimethyluric acid (5-8%) and unstable product 5-acetylamino-6-374 
formylamino-3-methyluracil (4-15%), with a small percentage (1-4%) of the initial dose excreted as 375 
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the parent compound (Carrillo and Benitez, 1994; Garattini, 1993). The list of caffeine metabolites 376 
identified in humans, together with the excretion rates can be found in Table S1. Besides being 377 
complex, caffeine metabolism is also rather variable, with the different excretion rates observed not 378 
only in different studies, but also between individuals within the same studies (Carrillo and Benitez, 379 
1994; Grant et al., 1983). These variations can be related with genetic differences (Blanchard et al., 380 
1985; Grant et al., 1983) or influenced by other factors, such as age (Blanchard et al., 1985; Grant et 381 
al., 1983), pregnancy ((Carrillo and Benitez, 1994; Garattini, 1993) or medications (Callahan et al., 382 
1983). However, certain metabolites, such as paraxanthine, 1,7-dimethyluric acid and 1-383 
methylxanthine were found to be less affected by the genetic background compared to the parent 384 
compound and they were, therefore, suggested as potential biomarkers for caffeine dietary intake 385 
(Crews et al., 2001). Furthermore, most of the pharmacokinetic data on caffeine metabolism in 386 
humans are quite old (Blanchard et al., 1985; Grant et al., 1983) and some of them include a 387 
relatively low number of subjects (Blanchard et al., 1985).  388 
Due to its wide usage in modern societies, caffeine is among the most ubiquitous wastewater 389 
micro-contaminants, usually detected at relatively high concentration levels (μg/L) in untreated 390 
wastewater (Martínez-Bueno et al., 2011; Rosal et al., 2010; Santos et al., 2009). Due to this, 391 
caffeine was proposed as anthropogenic marker to indicate the discharge of domestic wastewater in 392 
rivers and lakes (Buerge et al., 2003), but so far has been rarely used as a biomarker in a WBE 393 
approach. Caffeine has also been proposed as a human biomarker for assessing population size and 394 
the dynamics of people served by a particular WWTP (Daughton, 2012b) (see section 5.3).  395 
However, with the exception of paraxanthine, data on the occurrence of caffeine metabolites 396 
in wastewater are still very scarce. In fact, the first comprehensive study which included most of the 397 
major caffeine metabolites (1-methylxanthine, 7-methylxanthine and paraxanthine) was published 398 
just recently (Senta et al., 2015a). Concentrations of these metabolites found in Italian wastewater 399 
were similar to those of the parent compound, i.e. in the μg/L range. In the same work temporal and 400 
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spatial patterns of use were also studied and the mean mass loads of caffeine and its major 401 
metabolites revealed to be slightly lower during the weekend, probably due to the lower 402 
consumption of coffee. Similar findings for caffeine was reported by Rico et al. (Rico et al., 2016; 403 
Senta et al., 2015a). On the other hand, no clear geographical trends could be observed. Besides 404 
being easily detectable, caffeine, 1-methylxanthine, 7-methylxanthine and paraxanthine fulfill 405 
additional important requirement for an ideal biomarker - they are stable in wastewater samples 406 
stored at 4 °C and 20 °C for 24 h (Senta et al., 2015a). However, it is noteworthy that more research 407 
is needed in order to select the most suitable caffeine biomarker in wastewater for the correct 408 
interpretation of the obtained results within the concept of WBE.  409 
 410 
2.5. New Psychoactive Substances  411 
The detection of NPS and the estimation of their use are especially challenging for drug 412 
epidemiology, since new compounds appear continuously on the market and consumers do not 413 
always know the composition of the drugs they take. WBE can shed some light and provide 414 
additional information, but it is also affected by important challenges. First, pharmacokinetic data 415 
are essentially non-existent for most NPS, making it extremely difficult to define appropriate 416 
biomarkers. Second, the prevalence of abuse of a single substance is generally low, leading to very 417 
low concentrations in wastewater. Finally, their stability in this matrix is largely unknown 418 
(EMCDDA, 2016; Reid and Thomas, 2016). Based on the limited information available, this 419 
section attempts to present a selection of potential biomarkers, to be used in WBE studies, for the 420 
most common classes of NPSs: synthetic cannabinoids, synthetic cathinones, phenethylamines, 421 
piperazines, tryptamines, arylcycloalkylamines and benzodiazepines (EMCDDA, 2015a). The two 422 
first groups constitute the largest categories and also account for the majority of seizures in Europe 423 
(EMCDDA, 2015a).  424 
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Synthetic cannabinoids include a broad range of structurally different compounds sharing 425 
affinity for the cannabinoid receptors in the brain (Pertwee, 2008). Due to their recent increased 426 
popularity, their human metabolism is a growing area of research. Several in vitro and in vivo 427 
experiments have been performed over the past few years and, although individual pharmacokinetic 428 
profiles remain to be elucidated for many of them, it is generally thought that synthetic 429 
cannabinoids are extensively oxidized in the human body and excreted as a complex mixture of 430 
phase I and phase II metabolites (Fantegrossi et al., 2014; Seely et al., 2012). JWH-type 431 
cannabinoids are the most popular drugs within this class. Monohydroxylation, either at the N-alkyl 432 
side chain, the naphthyl moiety or the indole moiety (followed by the corresponding 433 
glucuronidation) has been identified as their major metabolic pathway and, in fact, 434 
monohydroxylated metabolites have been detected in urine from JWH-type cannabinoids 435 
consumers (Hutter et al., 2012; Ozturk et al., 2015; Wohlfarth et al., 2013). However, the lack of 436 
rigorous pharmacokinetic data, essential to calculate excretion rates, prevents from extrapolating 437 
these analyses to whole communities by the WBE approach. Another important limitation concerns 438 
their instability in wastewater: the scarce literature available suggests that some synthetic 439 
cannabinoids and their metabolites are highly labile and tend to get adsorbed to particle matter, 440 
hindering their determination and sub-estimating the potentially derived abuse calculations (Reid et 441 
al., 2014a, 2014b). As a reflection of these intrinsic difficulties, to the best of our knowledge only 442 
the metabolite JWH 018 N-5-hydroxypentyl and the parent compounds JWH-210 and JWH-122, 443 
have been positively detected in wastewater in two out of all the studies dealing with NPS in this 444 
matrix (Borova et al., 2015; Reid et al., 2014b) (see Table S1).  445 
Synthetic cathinones are known to have been abused for approximately 15 years and the 446 
synthesis of cathinone derivatives has been reported since the late 1920s (Hyde and Adams, 1928; 447 
Prosser and Nelson, 2012). They all refer to cathinone ((S)-2-amino-1-phenyl-1-propanone), a 448 
naturally occurring stimulant found in the leaves of Catha edulis (Khat) (Prosser and Nelson, 2012). 449 
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In general, the drugs are in part extensively metabolized in humans. However, some of the synthetic 450 
cathinones are also excreted unchanged in urine (Uralets et al., 2014). Details on the metabolism 451 
and detectability of synthetic cathinones can be found in original articles and are summarized in 452 
several review articles (Ellefsen et al., 2015; Helfer et al., 2007; Meyer et al., 2014, 2012, 2010a, 453 
2010b; Meyer and Maurer, 2010; Pawlik et al., 2012; Pozo et al., 2014; Shima et al., 2014; Staack 454 
and Maurer, 2005; Uralets et al., 2014; Welter-Luedeke and Maurer, 2015). Also, data on the 455 
stability, especially under storage conditions, were published (Senta et al., 2015b) and highlighted 456 
the possible instability of the parent compounds under alkaline conditions (Johnson and Botch-457 
Jones, 2013; Tsujikawa et al., 2012). However, detailed and comprehensive studies are missing on 458 
their chemical stability in wastewater and also biotransformation in the sewer or wastewater should 459 
be considered (McCall et al., 2016a). Several studies were published on the analysis of synthetic 460 
cathinones in wastewater samples, with mephedrone, methylenedioxypyrovalerone, methcathinone, 461 
methylone and α-pyrrolidinovalerophenone (α-PVP) being the most frequently detected (Borova et 462 
al., 2015; Chen et al., 2013; González-Mariño et al., 2016a, 2016b; Kinyua et al., 2015; 463 
Mwenesongole et al., 2013; Ocaña-González et al., 2015; Thai et al., 2016; Tscharke et al., 2016). 464 
Phenylethylamines are a class of substances related to amphetamine and methamphetamine, 465 
possessing psychoactive and stimulant effects; however, modification of these compounds can lead 466 
to potent hallucinogens (Zaitsu et al., 2011; Zawilska and Andrzejczak, 2015). They include 467 
amphetamine derivatives such as MDMA, 2C and ‘D’ series drugs. However, the phenethylamine 468 
core is shared among several compounds including cathinones and catecholamines. Several 469 
metabolism studies have been conducted in an effort to understand their metabolic profiles (Ewald 470 
et al., 2008, 2006; Lai et al., 2015b; Staack et al., 2003) but more information is needed.  471 
Piperazine-like compounds include the original member 1-benzylpiperazine (BZP), its 472 
methylenedioxy analogue and several phenylpiperazines. They are mainly known to bind to 473 
serotonin receptors, with BZP additionally producing amphetamine-like stimulant effects (Bye et 474 
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al., 1973; De Boer et al., 2001). A summary with details on the metabolism of piperazines can be 475 
found in some articles (Maurer et al., 2004; Staack et al., 2001; Staack and Maurer, 2005); 476 
furthermore, one study showed the detection of metabolites in human urine (Tsutsumi et al., 2005). 477 
Some examples are shown in Table S1. 478 
Tryptamine is a primary amine alkaloid found widely in nature in both the plant and animal 479 
kingdoms and known for its hallucinogenic effects (Collins, 2011). Metabolism of some synthetic 480 
tryptamines has been studied (Kamata et al., 2006; Michely et al., 2015; Narimatsu et al., 2008).   481 
Arylcycloalkylamines, which include the ketamine derivative methoxetamine (MXE) and 482 
phencyclidine derivatives, have emerged as legal alternatives to ketamine (Roth et al., 2013). MXE, 483 
which has gained popularity in several European countries (EMCDDA, 2014), is extensively 484 
metabolized (Meyer et al., 2013) but it was detected as parent MXE in wastewater from Belgium 485 
and Switzerland (Kinyua et al., 2015).  486 
Benzodiazepines are psychoactive substances whose core structure is a benzene ring fused 487 
to a diazepine ring. Benzodiazepines are known as tranquilizers and are among the most commonly 488 
prescribed antidepressant medications. Although a useful pharmaceutical, there is potential for 489 
abuse due to their hypnotic and sedative effects – even to the extent of being used as “date rape” 490 
drugs (Schwartz et al., 2000). From now on we will refer to those benzodiazepines used illegally as 491 
design benzodiazepines. Designer benzodiazepines have become a rapidly growing class of drugs 492 
on the NPS online market, since a medical prescription is not needed. Since designer 493 
benzodiazepines have increased in popularity, studies have been conducted characterizing their 494 
human metabolism (Huppertz et al., 2015; Moosmann et al., 2013).  495 
Up to now, no designer phenethylamines, tryptamines or designer benzodiazepines and 496 
metabolites have been detected in wastewater and only two studies has reported the stability of 497 
some phenylethylamines in wastewater (Bade et al., 2016; Senta et al., 2015b).  498 
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Although the interpretation of quantitative results should be done carefully for NPS due to 499 
the lack of metabolic information, the qualitative monitoring could lead to a better understanding of 500 
the frequency of use and could identify changes in consumption. 501 
 502 
3. EXPOSURE BIOMARKERS FROM ENVIRONMENT AND FOOD  503 
Two important exposure pathways for potentially harmful compounds are the dietary intake 504 
and the exposure from the surrounding daily environment. The monitoring of various classes of 505 
compounds for which exposure commonly occurs through these routes is necessary to safeguard 506 
public health. Representative chemical classes have been chosen as examples for this paper. 507 
Pesticides, mycotoxins and parabens are three classes of compounds for which exposure occurs 508 
through the intake of contaminated food or absorption through the skin and adverse health effects 509 
can be foreseen for humans (Błędzka et al., 2014; Heyndrickx et al., 2015; Rizzati et al., 2016; 510 
Warth et al., 2013). Exposure through the indoor environment (furniture, electronics, packaging and 511 
personal care products (PCPs)) is characteristic for UV-filters, plasticizers and brominated flame 512 
retardants. 513 
This section reviews the specific biomarkers of each of the above mentioned chemical 514 
classes which could be measured in wastewater in order to assess the overall exposure to these 515 
compounds through a WBE approach. When relevant, we have also included the metabolites of 516 
these chemicals to be explored as a suitable biomarker. The suggested biomarkers are reported in 517 
Table S2 including also metabolites, whenever such information is available.  518 
 519 
3.1 Pesticides  520 
Pesticides are chemicals commonly used for control of harmful organisms, such as fungi, 521 
insects and weeds. They are mostly used for crop protection, but can also be used for livestock 522 
protection, as well as for other industrial and household purposes, such as termite prevention. The 523 
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general population is exposed to pesticides mainly through diet (Ntzani et al., 2013), but also 524 
through household use (Trunnelle et al., 2013) and inhalation of polluted air - particularly in 525 
agricultural areas where aerial spraying of pesticides occurs (Coscollà et al., 2010). Exposure to 526 
pesticides is of public concern as they may cause health effects such as elevated rates of chronic 527 
diseases, like cancer or diabetes, as well as neurodegenerative disorders such as Parkinson disease, 528 
birth defects and reproductive diseases (Rizzati et al., 2016). Young children are the most 529 
susceptible to be at risk (European Food Safety Authority, 2013). 530 
There are several types of pesticides and they are generally classified by their chemical 531 
structure: carbamate, organophosphate or triazine pesticides (Table S2). They may also be 532 
classified by the type of pest they control, such as herbicides, which are intended to kill weeds and 533 
other unwanted plants, and insecticides, which kill insects and other arthropods. Pesticides are 534 
mostly formulated as mixtures with individual components which may act independently of each 535 
other, interact or have dose-addition effects (Hernández et al., 2013).  536 
Until now, there are only two WBE studies (Rousis et al., 2016a, 2016b) published on 537 
human exposure to pesticides. The first work (Rousis et al., 2016a) proposed for the first time a new 538 
application for pesticides, where pyrethroid, triazine and organophosphate metabolites were 539 
monitored in influent wastewater of seven Italian cities. The most frequently detected compounds 540 
were the specific metabolite of chlorpyrifos and chlorpyrifos-methyl, 3,5,6-trichloro-2-pyridinol 541 
(TCPY), the metabolite of diazinon (2-isopropyl-6-methyl-4-pyrimidinol, IMPY), the pyrethroid 542 
metabolites 3-phenoxybenzoic acid (3-PBA, common metabolite of about 20 pyrethroids), 3-(2,2-543 
dichlorovinyl)-2,2-dimethyl-(1-cyclopropane)carboxylic acid (DCCA, common metabolite of 544 
permetrin, cypermetrin and cyflutrin) and two alkyl phosphate metabolites. The second work 545 
(Rousis et al., 2016b) applied the novel WBE approach to assess further exposure to pyrethroids, 546 
concretely 3-PBA, cis-DCCA and trans-DCCA. The obtained results were in agreement with the 547 
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Human Biomonitoring (HBM) profiles in urine samples of the general population, reported in the 548 
literature.  549 
Yusa et al. 2015 reviewed analytical methods for HBM of pesticides and found that the most 550 
commonly biomonitored ones are carbamates, herbicides, neonicotinoids, organophosphates, 551 
pyrethroids and sulfonylurea herbicides – all of which can be monitored in urine samples and they 552 
can be good potential biomarkers for WBE. However, some other pesticide classes, such as 553 
organochlorines, are probably not suited to WBE due to their non-polar characteristics and their 554 
poor excretion in urine (Yusa et al., 2015).  555 
As described previously for other substances, the metabolites of pesticides rather than the 556 
parent substances should be measured in wastewater to avoid contributions from sources other than 557 
human metabolism. It has to be emphasized that some pesticide metabolites are also formed in the 558 
environment (i.e. atrazine undergoes dealkylation in water systems forming human metabolites) and 559 
therefore more research is needed.  Moreover, there are some common metabolites produced by 560 
different classes of compounds, such as organophosphate pesticides, organophosphate plasticizers 561 
and flame retardants, and this should be taken into account in a WBE approach. The novel method 562 
developed by Rousis et al. is considered as a valuable tool for obtaining objective, direct 563 
information on pesticide exposure levels and could provide complementary information for HBM 564 
studies. Table S2 presents the main potential biomarkers of exposure to pesticides selected by 565 
considering the detection frequency in urine, and the concentration levels (Barr, 2008; Yusa et al., 566 
2015).  567 
 568 
3.2  Mycotoxins  569 
Mycotoxins are toxic fungal metabolites that can be found in food and feed which are 570 
intended for human and animal consumption (i.e. cereals such as rice, maize and wheat). There is 571 
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huge concern of human health risks related to the ingestion of these substances, since they are stable 572 
in food processing and cooking. Maximum tolerable levels in food commodities were therefore 573 
legally established in many countries (Comission Regulation 1881/2006, 2006). While, nowadays, 574 
approximately 400 compounds belong to this group, only 10-15 are considered to be priority 575 
mycotoxins, due to higher occurrence and toxicity. These latter compounds belong to the groups of 576 
aflatoxins, ochratoxins, patulin and fusarium toxins (tricothecenes, fumonisins, zearalenone and 577 
zearalenone derivatives) (Anfossi et al., 2016; Turner et al., 2015). HBM studies performed on 578 
general population have shown that the most studied mycotoxin biomarkers in urine samples are 579 
aflatoxin M1 (AFM1), ochratoxin A (OTA), deoxynivalenol (DON), nivalenol (NIV), fumonisin B1 580 
(FB1) and zearalenone (ZON) (H Fromme et al., 2016; Heyndrickx et al., 2015). If mycotoxin 581 
contaminations are going to be increased in the near future due to higher global food demand and 582 
global climate and environment changes, new methods are needed to evaluate the human exposure 583 
to mycotoxins (Marroquín-Cardona et al., 2014). Thus, a novel approach such as the WBE can be 584 
useful to provide complementary information to existing methods.  585 
Few studies dealing with the determination of mycotoxins in wastewater have been 586 
published. The studied analytes were detected at very low concentrations (few ng/L), but at high 587 
detection frequency. In addition to parent compounds, some human metabolites were also 588 
investigated. The detected mycotoxins were DON, beauvericin (BEA), 3-Acetyldeoxynivalenol (3-589 
AcDON), NIV, ZON, α-zearalenol (α-ZOL) and β-zearalenol (β-ZOL) (Kolpin et al., 2014; Laganà 590 
et al., 2004; Schenzel et al., 2012, 2010; Wettstein and Bucheli, 2010). None of these studies 591 
attempted to apply the WBE approach to these substances; they had only a monitoring scope. In the 592 
present paper a selection of mycotoxins and their related potential biomarkers for a WBE approach 593 
were reported for the first time (Table S2). 594 
 595 
3.3  Parabens  596 
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Parabens are a group of chemicals that is drawing a lot of interest in the current discussion 597 
given their potential endocrine disrupting properties, since studies have shown that they have 598 
potential adverse health effects (Hu et al., 2013; Kim et al., 2015; Zhang et al., 2013). This has 599 
raised concern considering their widespread use. Parabens are used as preservatives in many 600 
different products, such as cosmetics, PCPs and foods, and can be commonly found in household 601 
products.  602 
Some studies also investigated the occurrence and fate of parabens in wastewater (González-603 
Mariño et al., 2009; Gracia-Lor et al., 2012a; Kasprzyk-Hordern et al., 2008), but not from a WBE 604 
perspective. Therefore, a list of known urinary biomarkers for paraben exposure is reported in 605 
Table S2. Future research should be addressed in order to explore paraben biomarkers for WBE.  606 
 607 
3.4.  UV-Filters  608 
Overexposure to ultraviolet (UV) radiation has been associated with skin disorders, such as 609 
cancer (Ramos et al., 2016). This led to the widespread usage of UV filters in a variety of personal 610 
care products to protect against UV radiation, i.e., sunscreen, cosmetics, beauty creams, body 611 
lotions, hair sprays and shampoos (Brausch and Rand, 2011). UV filters are also used in food 612 
packages, plastics and textiles to prevent polymer degradation. Hence, human exposure occurs 613 
through multiple routes such as dermal absorption, ingestion of contaminated food and tap water 614 
(Valle-Sistac et al., 2016). Two major types of UV filters are currently available; organic UV filters 615 
are used to absorb UVA and/or UVB radiation, whereas inorganic UV filters mainly reflect the 616 
radiation. Given the high photostability and lipophilicity, many UV filters can enter biological 617 
membranes and bioaccumulate in the body, including in the placental tissues (Valle-Sistac et al., 618 
2016).  However, it is important to note that most UV-Filters are released into the sewers without 619 
going through the body (Daughton and Ruhoy, 2009; Ruhoy and Daughton, 2008). This fact would 620 
contribute to a large uncertainty in its estimation. 621 
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Urinary analysis has frequently detected UV filters at various levels, demonstrating human 622 
exposure (Dewalque et al., 2014; Louis et al., 2015). Despite their widespread use, between 2010 623 
and 2015 only 20 studies have been published in peer reviewed journals dealing with UV filters 624 
detection in wastewater (Ramos et al., 2016). Yet, available data indicates that major UV filters 625 
groups, i.e. benzophenone derivatives, p-aminobenzoic acid derivatives, camphor derivatives, 626 
benzotriazole derivatives, salicylate derivatives, benzimidazole derivatives, triazine derivatives, 627 
cinnamate derivatives, crylene derivatives, and dibenzoyl methane derivatives, are ubiquitous in 628 
wastewater with concentrations ranging from the ng/L to the mg/L level (Gago-Ferrero et al., 2011; 629 
Rodil et al., 2012). Evidence from mammalian studies indicate that various UV filters are endocrine 630 
disruptors, acting as estrogenic, antiestrogenic, antiandrogenic or antithyroid (Louis et al., 2014). 631 
These results find support in recent epidemiologic studies reporting an association between human 632 
urinary levels of certain UV filters and couples fecundity, i.e. BP-2 (Louis et al., 2014), and 633 
decrease semen quality, i.e. BP-3 and BP-8. Therefore, (Louis et al., 2015) highlighted the 634 
importance of further studies exploring human exposure to UV filters. Despite the presence of UV 635 
filters has been reported in wastewater (Ramos et al., 2016; Tsui et al., 2014) no WBE approaches 636 
have been yet tested to evaluate human exposure to these substances. However, the high stability of 637 
these compounds and the indication of particular metabolite signatures (Le Fol et al., 2015) suggest 638 
potential biomarkers for UV filters in wastewater based biomarkers to support epidemiological 639 
studies (Table 1 and S2). 640 
 641 
3.5.  Plasticizers 642 
  Plastics are very versatile materials typically consisting of organic polymers of high 643 
molecular mass, which may contain other substances. Manufacturers often add different chemicals 644 
to plastics to give them specific characteristics, such as flexibility, resilience and pliability. These 645 
plasticizers mainly include phthalates and adipates, and because of their environmental persistence 646 
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and their widespread use, it is unsurprising that they can be found in wastewater and in the 647 
receiving environment (Barnabé et al., 2008; Gao and Wen, 2016; Olofsson et al., 2013; Zolfaghari 648 
et al., 2014). Some of these chemicals and/or their derivatives interfere with endogenous hormone 649 
signalization in animals and humans, raising concerns about their potential to cause long-term 650 
diseases (Joint Fao Oms Expert Committee On Food Additives, 2010). In particular phthalates (e.g. 651 
bis(2-ethylhexyl) phthalate and, dibutyl phthalate) were associated with the disruption of 652 
hormonally-mediated pathways, as well as increased risk for cancer (“Toxicological profile for 653 
di(2-ethylhexyl)phthalate (DEHP),” 2002, “Toxicological profile for Di-n-butyl-Phthalate,” 2001). 654 
Furthermore, epidemiological observational studies suggest that there is a consistent association of 655 
blood and urine concentrations of phthalates, and some effects, such as those mentioned above 656 
(Joint Fao Oms Expert Committee On Food Additives, 2010; Kim et al., 2015; Wang et al., 2016). 657 
Due to a better toxicological profile (Bhat et al., 2014) and a better blood compatibility (Zhong et 658 
al., 2013), other plasticizers, such as di-isononyl cyclohexane-1,2-dicarboxylate (DINCH), have 659 
been increasingly used in recent years as alternatives in PVC films and medical devices. 660 
Metabolites of phthalates, adipates, and DINCH have been found in urine (Fromme et al., 2016; 661 
Guo et al., 2011; Herrero et al., 2015; Loftus et al., 1993; Silva et al., 2007), but their presence in 662 
wastewater has never been investigated. For a list of known biomarkers in urine see Table S2. 663 
 664 
3.6  Flame retardants  665 
Flame retardants (FRs) are chemical additives for manufactured materials, such as plastics 666 
and textiles, to inhibit, suppress, or delay the production of flames to prevent the spread of fire. 667 
Brominated flame retardants (BFRs) and organophosphorus flame retardants (PFRs) are the most 668 
used classes of organic FRs. Due to their high log Kow, BFRs are lipophilic and preferentially 669 
retained in the human body, e.g. in the blood or adipose tissue. They are only slowly metabolized to 670 
hydroxylated metabolites (e.g. HO-PBDEs), which are also retained in the body and thus not 671 
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excreted in the urine. The presence of BFRs in the sewer system is largely due to direct input from 672 
the indoor environment, following washing out of dust and being associated with particles. PFRs 673 
are less persistent and rapidly metabolized in the human body (Van den Eede et al., 2013), they 674 
have been measured in municipal wastewater in Europe (Loos et al., 2012; Marklund et al., 2005), 675 
Australia (O’Brien et al., 2014) and United States (Schreder and La Guardia, 2014). PFRs 676 
metabolites are excreted via urine and they are thus suitable biomarkers to assess human exposure 677 
to PFRs (Van den Eede et al., 2015); however, there are no reports on the presence of PFR 678 
metabolites in wastewater and no studies testing them in a WBE approach (Table S2).  679 
 680 
4. HEALTH BIOMARKERS  681 
Community health programs play an essential role for public health agencies to monitor and 682 
evaluate the present status of health in a community and measure the success of programs aimed at 683 
improving it. Current challenges mainly consist of the quick and reliable evaluation of the overall 684 
health of a population, and detect possible health and illness threats such as pandemics or higher 685 
prevalence of diabetes or cancer. 686 
The quantitative measurement of specific exogenous and endogenous biomarkers related to 687 
these diseases in wastewater has the potential to provide rapid information on different factors 688 
related to public health and illness. Specific classes of pharmaceuticals such as antibiotics and 689 
benzodiazepines and their metabolites are exogenous compounds, which can be related to their use 690 
for specific illnesses or diseases, whereas endogenous compounds, such as α-fetoprotein, 691 
chroriogonadotropin (hCG) and isoprostanes, are more directly related to cancer or stress. 692 
In this section, both exogeneous and endogenous specific biomarkers are presented and 693 
suggested to monitor health issues (Table S3) through the WBE approach. In addition, DNA-based 694 
approaches, currently applied in the field of WBE, have been reviewed. 695 
 696 
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4.1 Pharmaceuticals  697 
4.1.1  Antibiotics  698 
Antibiotics (ABs) can be suitable biomarkers for representing human health status 699 
associated with bacterial infections. The determination of reliable data on their consumption is of 700 
interest as AB use is one of the main factors responsible for AB resistance (Euro-CDC, 2012). WBE 701 
may give a better understanding of real time use and misuse of ABs at the population level, by 702 
supporting for example prescription data from official sources and annual sales.  703 
Many ABs are excreted unchanged in urine (Castiglioni et al., 2006; Huang et al., 2011), 704 
hence, parent drugs are generally targeted as biomarkers (Table S3). However, the selection of a 705 
significant AB biomarker should not be limited to the parent drug only; in fact, the investigation of 706 
specific metabolites is adding specificity to the analysis avoiding biases coming from the direct 707 
disposal of the AB. This is particularly relevant for ABs widely used for veterinary treatments. The 708 
most targeted classes of ABs are β-lactams, quinolones and fluoroquinolones, sulphonamides, 709 
tetracyclines and macrolides. Apart from β-lactams that undergo easy hydrolysis, sulphonamides 710 
and macrolides are very persistent, and are therefore also detected in treated wastewater (Jelic et al., 711 
2012). Stability of the ABs metabolites in wastewater is less understood. 712 
The occurrence of ABs in influent wastewater has been widely investigated in several 713 
countries (Gracia-Lor et al., 2012b; Kümmerer, 2009; Verlicchi et al., 2012). Seasonal variability of 714 
population-normalized mass loads was observed by Castiglioni et al. 2006, using the WBE 715 
approach, showing a difference in percentage from winter to summer of 47, 77 and 100 for 716 
ciprofloxacin, ofloxacin and sulphamethoxazole, respectively (Castiglioni et al., 2006). Temporal 717 
monitoring of ABs at several time scales showed a higher variability monthly/hourly than 718 
daily/weekly along with seasonality in mass fluxes for ciprofloxacin, ofloxacin and clindamycin 719 
(Coutu et al., 2013). Deconjugation during in-sewer transport may influence the influent loading of 720 
sulfamethoxazole (Snip et al., 2016) depending on the type and size of the served catchment 721 
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(Polesel et al., 2016). Application of WBE helped in determining the usage of ABs in areas where 722 
consumption data were scarce or a proper regulation was missing, revealing an excessive use in 723 
China (Yuan et al., 2015).  724 
 725 
4.1.2 Benzodiazepines  726 
Benzodiazepines are used therapeutically for a considerable number of applications, 727 
including anxiety and sleep disorders. Their primary mode of action is an enhancement of the action 728 
of the neurotransmitter gamma-aminobutyric acid which may result in anticonvulsant, anxiolytic, 729 
hypnotic, muscle relaxant and sedative effects. Benzodiazepines and benzodiazepine analogs are 730 
commonly prescribed; however, they are also among the most frequently abused prescription 731 
medications (Button, 2015). Despite the risk for abuse, approximately 5.2% of US adults between 732 
18 and 80 years of age used benzodiazepines in 2008, with a double prevalence for women than 733 
men (Olfson et al., 2015). As such, monitoring of benzodiazepines is of public concern.  734 
Monitoring benzodiazepines in populations could be achievable via WBE as they are 735 
normally halogenated and hence resistant to biodegradation (Kosjek et al., 2012). Multiple studies 736 
have already identified both parent benzodiazepines and their urinary metabolites in wastewater 737 
influent (Baker et al., 2014; Borova et al., 2014; Castrignanò et al., 2016; Fernández et al., 2014; 738 
Hummel et al., 2006; Kosjek et al., 2012; Racamonde et al., 2015, 2014). Differences in the 739 
behavior of benzodiazepines are associated with differences in functional substituent groups, and 740 
mainly the hydroxylated tranquilizers, oxazepam, and temazepam, were reported to be present in 741 
influent and effluent wastewater (Bijlsma et al., 2012; Hummel et al., 2006; Löffler et al., 2005). 742 
A summary of the most commonly prescribed and detected benzodiazepine parent 743 
compounds and their metabolites, which have been identified in urine, in addition to identification 744 
in wastewater and stability data, when available, are presented in Table S3.  745 
 746 
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4.1.3 Other pharmaceuticals  747 
Even if many works have analysed the presence of pharmaceuticals in urban wastewater, 748 
only a few studies investigated these chemicals as WBE biomarkers. Some examples can be found 749 
in Table 1. Furthermore, a list of proposed pharmaceuticals is given in Table S3 with their 750 
excretion rates.  751 
 752 
4.1.4. Chiral pharmaceuticals  753 
 More than 50% of pharmaceuticals currently used are chiral although they are usually 754 
manufactured as racemic mixtures (Petrie et al., 2015; Vazquez-Roig et al., 2014). Human 755 
metabolism and microbial processes during wastewater treatment can result in the enrichment of 756 
one specific enantiomer. Thus, the analysis of chiral compounds in wastewater allows to distinguish 757 
between usage of pharmaceuticals due to intentional human ingestion and from accidental release 758 
(direct disposal). For instance, enantioselective analysis was used by (Vazquez-Roig et al., 2014) to 759 
tentatively propose direct disposal of atenolol where a moderate higher average daily load was 760 
observed. Recently, (Petrie et al., 2016) identified direct disposal of the antidepressant fluoxetine 761 
via the sewer network using wastewater analysis. 762 
 763 
4.2. Endogenous compounds  764 
Endogenous chemicals are produced by biological processes associated with stress or 765 
normal metabolism. Changes in biological mechanisms may result in alterations of the endogenous 766 
compound production and, therefore, measurement of such compounds can be used as indicator of 767 
health status and disease (Daughton, 2012b; Group, 2001; Hagger et al., 2006). Endogenous 768 
biomarker analysis has been extensively studied as diagnostic or prognostic tools in clinical 769 
medicine, and can be further applied to the field of WBE (Daughton, 2012b). Thus far, the 770 
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investigation of endogenous biomarkers has been more focused on diseases such as cancer, diabetes 771 
and cardiovascular disorder than on the overall health status. However, the number of biomarkers 772 
validated for routine clinical practice is rather limited (Poste, 2011; Rifai et al., 2006), which falls 773 
into even smaller numbers of biomarkers for WBE when considering only those excreted into urine. 774 
Nevertheless, a range of endogenous compounds have been suggested as wastewater biomarkers of 775 
effect including cancer (prostate specific antigen, α-fetoprotein) (Thomas and Reid, 2011; Yang et 776 
al., 2015c), oxidative stress (isoprostanes) (Daughton, 2012b; Ryu et al., 2015; Thomas and Reid, 777 
2011) and health (anti-inflammatory eicosanoids) (Daughton, 2012b). To date, studies conducted on 778 
candidate endogenous biomarkers in wastewater are based on targeted analysis of specific markers 779 
such as isoprostanes (Ryu et al., 2015) and cancer biomarkers (Yang et al., 2015c). However, it is 780 
important to note that omics approaches also hold promising and important roles in future 781 
developments and applications of endogenous biomarkers analysis in WBE (Rice et al., 2015). The 782 
added value of analyzing these compounds would reside mainly in relative comparisons, both intra- 783 
and inter- communities (Daughton, 2012b). Compared to the interpretation of the exogenous 784 
biomarkers, where absolute values are emphasized, the use of endogenous biomarkers is more 785 
focused on detecting changes over time or between communities. Such data can reveal emerging 786 
trends (i.e., early warning system) and health disparities caused by various factors (e.g., exposure, 787 
lifestyle). 788 
 789 
4.3. DNA  790 
The demand for sensitive, low-cost and high-throughput methods to characterize DNA/RNA 791 
sequences has driven the development of molecular biology techniques and bioinformatics, i.e., 792 
PCR-based approaches and next generation sequencing (NGS) (Ryoo et al., 2013). Massive 793 
sequencing is nowadays possible, owing to the development of different NGS platform that allows 794 
an entire genome to be sequenced in less than one week. These technical advances led to a rapid 795 
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increase in new applications, including DNA-based health biomarkers. During the last decade an 796 
increasing number of studies took advantage of these developments, and applied them to the field of 797 
WBE. Several examples highlight the potential of the approach. In the field of virological 798 
surveillance, wastewater screening has been used to identify the viral strains that are circulating in 799 
the community, supporting epidemiological studies of the related viral infections and working as an 800 
early warning tool (Hellmér et al., 2014; Kokkinos et al., 2011; Mclellan et al., 2013; Zhou et al., 801 
2014). Hellmér et al. 2014 investigated the presence of eight pathogenic viruses (norovirus, 802 
astrovirus, rotavirus, adenovirus, Aichi virus, parechovirus, hepatitis A virus [HAV], and hepatitis E 803 
virus) in wastewater from Sweden to explore whether their identification could be used as an early 804 
warning of outbreaks. Results show that two strains were involved in an ongoing outbreak in 805 
Scandinavia and were also identified in samples from patients with acute hepatitis A in Gothenburg 806 
during spring of 2013.  807 
A similar framework has been applied in other areas such as the study of the epidemiology 808 
of the emerging human pathogens (Mclellan et al., 2013; Webb et al., 2015), and antibiotic 809 
resistance patterns of populations (Colomer-Lluch et al., 2014; Kumaraswamy et al., 2014; 810 
McLellan and Eren, 2014). One of the most recent applications has been in the field of human 811 
metabolic disorders. With the obesity epidemic reaching alarming levels, there is a need to set 812 
biomarkers to identify populations or sub-populations at risk (Lyssimachou et al., 2015). Recently, 813 
a good correlation has been established between the gut microbiome and obesity. In fact, only a few 814 
bacterial species are sufficient to distinguish between lean and obese individuals (Le Chatelier et al., 815 
2013). These findings prompted a large study in the US using oligotyping of high-throughput 16S 816 
rRNA gene sequence data to screen wastewater from 71 cities. It was demonstrated that cities could 817 
be differentiated by their sewage bacterial communities, and the community structures were good 818 
predictors of a city’s estimated level of obesity (Newton et al., 2015). This example illustrates that 819 
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once specific biomarkers are identified, DNA-based analysis in wastewater can work as a powerful 820 
tool to support epidemiological studies 821 
 822 
5. POPULATION BIOMARKERS  823 
Accurate estimation of population size is necessary to normalize WBE data to the per capita 824 
level, which allows for temporal and spatial comparisons to be made (van Nuijs et al., 2011b). A 825 
review of all uncertainties associated with WBE found that there is a direct relationship between the 826 
uncertainty in measuring the population size and the uncertainty in the calculated daily loads of 827 
drugs (Castiglioni et al., 2013; Lai et al., 2015a). Therefore, accurate data on population size are 828 
needed to make decisions involved with planning and forecasting, assessing services and 829 
infrastructure, policy making, informing legislation and resource allocation at the level of 830 
neighborhood, city, province or country.  831 
Current methodologies to estimate population size are based on public surveys (such as 832 
census taking), complemented with a wide array of demographic statistics, such as tourism and 833 
potential commuters. Census, however, can become increasingly outdated and cannot be easily 834 
updated to accommodate change such as births, deaths, and migration (movement). Ideally, the 835 
census should be able to estimate both the de jure and the de facto population. The de jure 836 
population comprises all “usual” residents, mainly those with formal residences. The de facto 837 
population comprises all those who are present, regardless of the location of their formal or usual 838 
residence (Daughton, 2012a). A de facto population therefore includes all non-residents (e.g., 839 
commuters, visitors, tourists) and excludes all permanent residents who are absent. However, the 840 
census approach acquires a static snapshot estimate and usually succeeds in only capturing a portion 841 
of the population. Population size can also be estimated from hydrochemical parameters that are 842 
routinely determined in the WWTPs, including chemical oxygen demand (COD), biological oxygen 843 
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demand (BOD) and total nitrogen and phosphorus. However, these parameters are highly influenced 844 
by wastewater composition (i.e. industrial, domestic or mixed).  845 
Addressing the population uncertainty and identifying suitable markers for the population 846 
size markers is thus an important aspect of WBE (Been et al., 2014; Brewer et al., 2012; Lai et al., 847 
2011; O’Brien et al., 2014). Many compounds can be considered as biomarkers for population size. 848 
Possible candidates are both naturally occurring and synthetic xenobiotics (and their metabolites or 849 
formulation impurities), as well as products of endogenous metabolism. A variety of chemicals 850 
have been studied as biomarkers of population, including drugs (e.g., carbamazepine (Gasser et al., 851 
2010)), biocides (e.g., triclosan (Singh et al., 2010)), chemicals in household cleaning agents, e.g., 852 
fluorescent whiteners, trialkylamines (Managaki et al., 2006; Valls et al., 1989), and food additives, 853 
e.g., sucralose (Oppenheimer et al., 2011). An essential characteristic for a biomarker to be useful 854 
for measuring population size is, in addition to the general requirements for a biomarker, to have a 855 
low variance in the per capita daily excretion (Daughton, 2012a); the knowledge of quantities 856 
excreted daily ensures that diurnal variations (e.g., resulting from circadian biorhythms) are fully 857 
accommodated. Another requisite for these groups of biomarkers is that daily per capita excretion 858 
should not be affected by variables such as season, weather and geographic location.   859 
 To date, none of the population size markers proposed have yet met all necessary criteria 860 
mentioned above and additional characteristics described before for a WBE biomarker should also 861 
be considered. Some specific applications are listed below. 862 
 863 
5.1 Artificial sweeteners 864 
The most popular artificial sweeteners used in foodstuffs include acesulfame (ACE), alitame 865 
(ALI), aspartame (ASP), cyclamate (CYC), neotame (NEO), neohesperidin dihydrochalcone 866 
(NHDC), saccharin (SAC) and sucralose (SUC) (Table S4) (Kokotou et al., 2012; Lange et al., 867 
2012). All of them, except NEO and ALI, are allowed to be used as additives in food by the 868 
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European Union (EPCD, 2003), whereas five of them, ACE, ASP, NEO, SAC and SUC are 869 
approved to be used in the United States (USFDA, 2006).  870 
After ingestion, ACE, CYC and SAC are unaffected by the human metabolism, and thus 871 
largely eliminated from human bodies mainly unchanged in urine (Fermin and Vallvey, 2004; 872 
Lange et al., 2012; Renwick, 1985; Roberts et al., 2000; Sardesai and Waldshan, 1991). Studies 873 
have shown that, due to variations in individual metabolism, CYC could be metabolized to 874 
cyclohexylamine and excreted in urine (Renwick et al., 2004). For ALI, 7–22% is excreted 875 
unchanged in feces, while the rest, about 78–93% is hydrolyzed to aspartic acid and alanine amide 876 
(Fermin and Vallvey, 2004). The glucuronide conjugates of ALI metabolites are the major urinary 877 
metabolites in the first 24 hours. ASP is largely broken down in human gut to aspartic acid, 878 
phenylalanine and methanol (Fermin and Vallvey, 2004; Lange et al., 2012). NEO and its 879 
metabolites are excreted in urine and feces (WHO Food Additive Series No. 52, 2004). Less than 880 
2% is excreted unchanged, but it is extensively metabolized in humans via de-esterification to N-[N-881 
(3,3-dimethylbutyl)-L-alpha-aspartyl]-L-phenylalanine (WHO Food Additive Series No. 52, 2004). 882 
Minor metabolites of NEO include N-(3,3-dimethylbutyl)-L-aspartic acid, 3,3-dimethylbutanoic 883 
acid and the carnitine conjugate and glucuronide conjugate of 3,3-dimethylbutanoic acid (WHO 884 
Food Additive Series No. 52, 2004). NHDC is hydrolyzed in humans to isoferulic acid, 3-885 
hydroxyphenylpropionic acid, and 3-hydroxycinnamic acid (Fermin and Vallvey, 2004; Lange et 886 
al., 2012). SUC is mainly excreted unchanged in human feces, while 8-22% was excreted in urine 887 
unchanged together with its glucuronide conjugates (Roberts et al., 2000). 888 
ACE, CYC, SAC, and SUC were found highly stable in raw wastewater at 4oC and room 889 
temperature over four days (Ordóñez et al., 2012). Under these conditions, only 20-30% of ASP 890 
remained after one day and none left after two days. Similarly, the amount of NHDC was found less 891 
than 10% in the raw wastewater at 4oC after one day and linearly decreased at room temperature 892 
over three days. Similar results were also reported in another study, in which ACE, CYC, SAC and 893 
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SUC remained stable in raw wastewater at 4oC over three weeks, whereas ASP and NHDC were 894 
degraded within a day (Tran et al., 2013). 895 
Since they are exclusively non-metabolized in humans and highly stable in wastewater, the 896 
parent compounds ACE, CYC, SAC and SUC can be measured for the WBE approach. However, 897 
the analysis of the metabolites of ALI, ASP, NEO and NHDC, rather than of the parent compounds, 898 
is required, since these artificial sweeteners are largely metabolized in humans. Stability tests for 899 
the metabolites in raw wastewater are also necessary for future studies. The use of artificial 900 
sweeteners has been shown to be highly related to human activities (Buerge et al., 2009) and, 901 
therefore, human consumption is considered as the major source of these substances in raw 902 
wastewater; however, other sources, such as animal feedings, agriculture farms and industries, can 903 
contribute to their presence in sewage systems (Kokotou et al., 2012).  904 
Certain artificial sweeteners also showed a specific weekly pattern: in general higher loads 905 
in influents (i.e. consumption) were observed during weekdays than during weekends (Kokotou et 906 
al., 2013). This could be associated with more commuters during the weekday than the weekend in 907 
the studied catchment. These previous studies together suggested that measuring artificial 908 
sweeteners could be useful for the WBE approach to understand the population flow in a given 909 
catchment. This concept of using human consumed chemicals, such as the artificial sweetener ACE, 910 
to back-estimate the population size from a given wastewater sample was firstly attempted and 911 
discussed by (Lai et al., 2011) and further refined using wastewater samples collected on the census 912 
day and applying a Bayesian model (O’Brien et al., 2014). Importantly, with chemical-derived 913 
population estimates, the robustness of the WBE data was improved, since the total methodological 914 
uncertainty of the approach was reduced (Lai et al., 2015a, 2011). 915 
 916 
5.2. Nicotine 917 
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Currently, nicotine and its metabolites have been used as population markers on two 918 
occasions (Chen et al., 2014; Senta et al., 2015a). In the first case, the authors focused solely on 919 
cotinine, whose loads varied only limitedly over one week and showed good correlation with the 920 
size of the investigated populations (i.e., correlation coefficient = 0.981) (Chen et al., 2014). 921 
However, geographical/cultural differences in tobacco use or fluctuations in the number of users 922 
have been raised as potential flaws to the use of cotinine as population marker (Chen et al., 2014). 923 
Moreover, consumption of tobacco could change due to tax and other tobacco-related policies, 924 
which could affect the potential of nicotine and its metabolites as population markers.  In the second 925 
study (Senta et al., 2015a), cotinine and trans-3’-hydroxycotinine loads were used to estimate the 926 
number of individuals contributing to the collected wastewater samples. Good agreement was found 927 
between nicotine metabolite load population estimates and census data, suggesting that the method 928 
is a viable approach to estimate the size of a population.  929 
 930 
5.3. Caffeine 931 
Caffeine and some of its major metabolites were recently tested as a population biomarkers. 932 
Caffeine was one of the compounds included in the exploratory study to estimate population size 933 
using samples collected on the census day and applying a Bayesian model (O’Brien et al., 2014). A 934 
strong correlation between caffeine mass loads and population size was observed. In the second 935 
study, generally good agreement between caffeine loads and hydrochemical parameters routinely 936 
determined at the WWTPs was found (Rico et al., 2016). In another recent study, three major 937 
caffeine metabolites: 1-methylxanthine, 7-methylxanthine and paraxanthine were tested together 938 
with caffeine as possible population biomarkers (Senta et al., 2015a). These compounds fulfilled 939 
some of the major requirements for an ideal biomarker - they are easily detectable and stable in 940 
wastewater samples. However, their mass loads in wastewater did not completely reflect the human 941 
excretion profile of caffeine, probably due to biases in caffeine pharmacokinetic data (see section 942 
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2.4 and Table S2) and additional sources of some metabolites and unconsumed caffeine. This 943 
makes the possibility of using caffeine and/or its metabolites as biomarkers for population size 944 
assessment rather difficult, at least without additional studies. 945 
 946 
5.4. Pharmaceuticals 947 
Concentrations and mass loads of pharmaceuticals in wastewater were used in the WBE field 948 
for the estimation of population size only on three occasions (Lai et al., 2011; O’Brien et al., 2014; 949 
Rico et al., 2016). The investigated compounds by Lai et al. (Lai et al., 2011) were atenolol (beta-950 
blocker), gabapentin (anti-convulsant), hydrochlorothiazide (diuretic), and venlafaxine (anti-951 
depressant). Atenolol was concluded to be the best option for this aim for the specific catchment. In 952 
addition to the compounds selected by Lai et al., the same group also investigated carbamazepine 953 
(antiepileptic), codeine, ibuprofen, paracetamol (analgesics), furosemide (diuretic), iopromide 954 
(contrast medium), naproxen (anti-inflammatory) and salicylic acid (metabolite of acetylsalicylic 955 
acid) and the measured loads were used in a collective model for the estimation of the population 956 
size (O’Brien et al., 2014). By cross validating the data, the authors demonstrated that large 957 
populations sizes could be estimated fairly accurately using the information of multiple chemical 958 
mass loads. However, it could not be improved for small populations. In the work published by 959 
(Rico et al., 2016) twelve human urine biomarkers were tested to estimate population size, six of 960 
them being pharmaceuticals (hydrochlorothiazide, carbamazepine, codeine, naproxen, salicylic acid 961 
and atenolol). However, by using these compounds, the population was under or overestimated 962 
compared to the hydrochemical population, but they have good prospects if the appropriate data 963 
sales are available.  964 
 965 
5.5. Endogenous compounds 966 
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An alternative for estimating the population size in the catchment area of a WWTP relies on 967 
monitoring influent wastewater for a biomarker linked to human metabolism. Chemicals involved 968 
in endogenous metabolism avoid many of the problems encountered with xenobiotics, since their 969 
association with human activities has a higher fidelity. Yet, their main problem is excessive intra- 970 
and inter-individual variation in excretion. Biomarkers of endogenous origin derive from human 971 
biochemical processes and undergo continuous urinary or fecal excretion. Several endogenous 972 
biomarkers, which have been considered in the past or which have the potential to estimate the 973 
population size more accurately (Table S4), are further discussed.   974 
An important endogenous biomarker, widely used in clinical chemistry and with detailed 975 
knowledge about its excretion, is creatinine (CR). A small portion of creatine (and 976 
phosphocreatine), which is stored predominately in skeletal muscle, is continually converted to 977 
form the endogenous anhydride, CR (a nitrogenous waste product cleared via the kidney); the rate 978 
of conversion, in males for example, is about 1.6–1.7% per day. The major factors involved with 979 
variability in CR output have been summarized by (Ryan et al., 2011). However, intra- and inter-980 
day CR excretion is not constant and daily excreted quantities can have high variance, being 981 
strongly influenced by diet composition. In addition, CR is being increasingly used as a food and 982 
nutritional supplement, adding yet another source of potential variation to CR excretion rates. 983 
Although CR has been used in WBE studies as population marker (Brewer et al., 2012; Chiaia et 984 
al., 2008), it was shown to be unstable in wastewater (completely decomposed within 24 h) (Chen 985 
et al., 2014).  986 
Another potential biomarker is coprostanol (CoP) that originates from gut microbial 987 
metabolism, making up roughly 60% of the overall sterol content in human feces. CoP is poorly 988 
absorbed from the gut (it does not undergo enterohepatic circulation) and is therefore fully excreted 989 
in the feces. Since the 2000s, CoP has been used as anthropogenic marker in wastewater and to 990 
gauge the degree of dilution of raw or treated wastewater in receiving surface water (Takada and 991 
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Eganhouse, 1998). However, CoP is excreted by various vertebrates in differing absolute and 992 
relative quantities and it is sometimes difficult to distinguish between human and animal 993 
contamination (Bull et al., 2002). Furthermore, CoP adsorbs substantially onto particulate matter 994 
found in wastewater and was thus discarded as potential population marker (Chen et al., 2014). 995 
Similar results were obtained for cholesterol (Chen et al., 2014); cortisol and androstenedione were 996 
investigated, but rapidly degraded in wastewater (Chen et al., 2014).  997 
Another example of biomarker relatively unique to human metabolism is 1-aminopropan-2-998 
one (1-aminopropanone: APR; 1-aminoketone). Through 1-aminopropan-2-ol, APR serves as a 999 
precursor to vitamin B-12 (Fitzsimons and Belt, 2005). It is very water soluble and it is excreted via 1000 
urine, but in much lower daily quantities than CoP. However, it is sometimes found in wastewater 1001 
at levels higher than in urine, implicating potential de novo microbial formation in sewage 1002 
(Fitzsimons and Belt, 2005), whilst it could not be detected on other occasions (Singh and 1003 
Gardinali, 2006). 1004 
5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, has also been investigated. 1005 
Its excretion might be altered due to diseases (e.g., carcinoid tumors (Zuetenhorst, 2004)) and diet 1006 
(i.e., some fruits and nuts (Feldman and Lee, 1985) and salt intake (Sharma et al., 1993). 1007 
Furthermore, intra- and inter-individual variability in excretion has also been highlighted (Curtin et 1008 
al., 1996). Results from wastewater analysis showed good correlation with census data and the 1009 
authors considered it as a promising marker (Chen et al., 2014).  1010 
Ammonium (NH4+) represents the major form in which ammonia (NH3) is found in 1011 
wastewater and originates from the breakdown of urea (Udert et al., 2006). It is mainly introduced 1012 
via toilets (Butler et al., 1995) and it is routinely measured by WWTP as a water quality parameter. 1013 
It is supposedly less affected by non-human sources compared to conventional parameters (e.g., 1014 
chemical or biological oxygen demand, total phosphorous) (van Nuijs et al., 2011b) and can 1015 
potentially be measured online using ion-selective electrodes. Fluctuations in ammonium loads have 1016 
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been shown to link well to population dynamics (Been et al., 2014). Yet, its use to estimate absolute 1017 
figures of the size of the de facto population might be undermined in rural areas due to the 1018 
contribution of agricultural sources.  1019 
 1020 
5.6. DNA 1021 
Deoxyribonucleic acid (DNA) is a nucleic acid that carries most of the genetic instructions 1022 
from all known living organisms and many viruses. DNA can be naturally shed into the 1023 
environment through urine, feces, exudates or tissue residues. Compared to most of chemical 1024 
compounds as a candidate of population biomarkers, DNA is much more stable and able to persist 1025 
in the environment from month to hundred years depending on species (Prüfer et al., 2014; 1026 
Thomsen and Willerslev, 2015). DNA biomarkers have been widely used in the field of medical 1027 
diagnostics and biomedicine (Altintas and Tothill, 2013; Liu et al., 2011; Ralla et al., 2014; Wang et 1028 
al., 2012). For WBE, DNA has a great potential to act as a population biomarker, not only because 1029 
of its little affinity to other species in wastewater and constant excretion by humans, but also for its 1030 
extreme stability and the possibility of being quantifiable Those robotic characteristics well meet 1031 
the proposed criteria of a proper population biomarker candidate (Dejean et al., 2011; Thomsen and 1032 
Willerslev, 2015). 1033 
Typically, the changes of DNA component and structure such as DNA damage, repair and 1034 
mutation could be used as biomarkers. Recently, a H2AX histone phosphorylation assay was 1035 
developed as DNA damage biomarker for human population study, as it represents an early event in 1036 
the cellular response against DNA double-strand breaks (Sánchez-Flores et al., 2015). However, to 1037 
select a population biomarker for WBE uses, one of the crucial criteria is to screen human specific 1038 
DNA. Wastewater is a complex matrix, which may contain DNA from various species such as 1039 
plants, animals, and viruses. A recent study by Yang et al (Yang et al., 2015a, 2015b) has proposed 1040 
to use community sewage sensors to identify human-specific mitochondrial DNA as a potential 1041 
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population biomarkers. In this study, human specific mitochondrial DNA associated with disease 1042 
biomarkers (Liu et al., 2011; Tipirisetti et al., 2014) was amplified from wastewater by a 1043 
specifically designed primer using quantitative real-time polymerase chain reaction (PCR) (Yang et 1044 
al., 2015a). More importantly, the amplicons were detectable by an electrochemical biosensor based 1045 
on a custom synthesized ferrocence intercalator as a signal transducer. The developed biosensors 1046 
allow for the detection of single nucleotide variation and enable the potential of portable sensors for 1047 
rapid identification of specific human biomarkers in wastewater.  1048 
1049 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 1050 
WBE is a rapidly developing scientific discipline with a strong transdisciplinary character. It 1051 
has shown great progress, and opens up many possibilities for expanding its application to provide 1052 
relevant information about lifestyle and public health.  1053 
This review has outlined potential wastewater biomarkers of exposure or effect that could be 1054 
used for future applications associated with lifestyle and wellbeing studies. However, it has also 1055 
discussed limitations and highlighted that more research is needed, for various proposed 1056 
biomarkers, before WBE can appropriately be applied. Moreover, several trends, needs and 1057 
recommendations are indicated: 1058 
- Human pharmacokinetic data (metabolism and urinary profile of excretion) are necessary to 1059 
ensure that the candidate biomarker is formed in the body in a high proportion and is excreted 1060 
mainly via urine. This information is highly relevant not only to back-calculate the 1061 
consumption/exposure of a certain substance by a community, but also to distinguish the 1062 
amount of a substance coming from human or other sources.  1063 
- In-sample and in-sewer stability studies are needed for a better application in WBE. Stability 1064 
tests are often performed in the laboratory, trying to reproduce the real conditions of 1065 
temperature and sewage composition or in-sewer conditions. An alternative would be the use of 1066 
in-silico tools to predict the stability of a compound in wastewater treatment processes. These 1067 
models do not guarantee the formation of a biotransformation product, so it may be used as an 1068 
indicator or a guide about the in-sewer stability of a residue and its potential adsorption (Reid 1069 
2014). Sorption onto the solid particulate or the conjugation of the biomarkers must also be 1070 
taken into account when assessing stability.   1071 
- Source identification is needed to ensure that discharges from exogenous sources that might 1072 
cause overestimation of the real amounts consumed are considered.  1073 
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- Cross validation of data (e.g. concentrations of pharmaceuticals in wastewater with bench-top 1074 
sales) is recommended for all applications. 1075 
- Multiple biomarkers for estimating the population size need to be set to allow for the 1076 
normalization of the data. The development of portable biosensors may allow rapid estimation 1077 
of the population contributing to the wastewater samples in the near future. 1078 
- Regular monitoring of sewage for viruses based on similar DNA biosensors may give an early 1079 
warning of a possible upcoming outbreak.  1080 
- Omics approaches also hold promising and important roles in future developments and 1081 
applications of endogenous biomarkers analysis in WBE. 1082 
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TABLES 1108 
 1109 
Table 1. Overview of the most relevant biomarkers used so far and potential biomarkers (for more 1110 
details, please read the corresponding text and/or supporting information). 1111 
 1112 
Class Parent compound 
Biomarker/potential 
biomarker 
WBE 
application 
Reference 
Illicit drugs 
Cocaine Benzoylecgonine YES 
(Castiglioni and 
Gracia-Lor, 
2015; Gracia-
Lor et al., 2016) 
Amphetamine Amphetamine YES 
(Castiglioni and 
Gracia-Lor, 
2015; Gracia-
Lor et al., 2016) 
Methamphetamine Methamphetamine YES 
(Castiglioni and 
Gracia-Lor, 
2015; Gracia-
Lor et al., 2016) 
MDMA MDMA YES 
(Castiglioni and 
Gracia-Lor, 
2015; Gracia-
Lor et al., 2016) 
THC/Cannabis THC-COOH YES 
(Castiglioni and 
Gracia-Lor, 
2015; Gracia-
Lor et al., 2016) 
Alcohol Ethanol Ethyl sulfate YES 
(Rodríguez-
Álvarez et al., 
2015) 
Tobacco Nicotine 
Cotinine + trans-3'-
hydroxycotinine 
YES 
(Castiglioni et 
al., 2015b) 
Caffeine Caffeine See Table S1 NO  
NPS  See Table S1 NO  
Pesticides 20 pyrethroids 
 3-PBA YES (Rousis et al., 
2016b) 
Permetrin, 
cypermetrin, 
cyflutrin cis-DCCA YES 
(Rousis et al., 
2016b) 
Permetrin, 
cypermetrin, 
cyflutrin trans-DCCA YES 
(Rousis et al., 
2016b) 
Mycotoxines  See Table S2 NO  
Parabens  See Table S2 NO  
UV-filters  See Table S2 NO  
Plasticizers  See Table S2 NO  
Flame  See Table S2 NO  
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retardants 
Pharmaceuticals 
Atenolol Atenolol YES 
(Baz-Lomba et 
al., 2016; van 
Nuijs et al., 
2015) 
Citalopram Citalopram YES 
(Baz-Lomba et 
al., 2016; van 
Nuijs et al., 
2015) 
Carbamazepine Carbamazepine YES 
(Baz-Lomba et 
al., 2016; van 
Nuijs et al., 
2015) 
Diclofenac Diclofenac YES 
(Baz-Lomba et 
al., 2016) 
Metformin Metformin YES 
(van Nuijs et al., 
2015) 
Valsartan Valsartan YES 
(van Nuijs et al., 
2015) 
Benzodiazepines Oxazepam Oxazepam YES 
(Baz-Lomba et 
al., 2016) 
Artificial 
sweeteners 
Acesulfame Acesulfame YES 
(Lai et al., 
2015a) 
Endogenous 
Compounds 
Serotonin 5-HIAA YES 
(Rico et al., 
2016) 
Ammonia Ammonium YES 
(Been et al., 
2014) 
 1113 
 1114 
1115 
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FIGURE CAPTIONS 1116 
 1117 
Figure 1. Main requirements of a biomarker 1118 
1119 
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